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ABSTRACT A guanosine analog, 9-[(1,3-dihydroxy-2-pro-
poxy)methyl]guanine (DHPG), was found to inhibit herpes sim-
plex virus type 1 (HSV-1), herpes simplex virus type 2, cytomeg-
alovirus, and Epstein-Barr virus replication by >50% at con-
centrations that do not inhibit cell growth in culture. The potency
of the drug against all of these viruses is greater than that of 9-
[(2-hydroxyethoxy)methyl]guanine (acyclovir). DHPG was active
against HSV-1 growth during the early phase of virus replication
and had no activity when added at a later time after infection. Its
antiviral activity was irreversible. Thymidine partially neutral-
ized its action. The anti-HSV-1 activity of DHPG was dependent
on the induction and the properties -of virus-induced thymidine
kinase. Virus variants that induced altered virus thymidine kinase
and became resistant to acyclovir were still as sensitive to DHPG
as the parental virus. DHPG is active against five different HSV




FIG. 1. Structure of DHPG.
Cells infected by herpesviruses, which are important causes of
human diseases, undergo many biochemical changes, among
which are changes in several virus-specified enzymes that are
involved in either deoxynucleotide or DNA metabolism (1).
Nucleoside analogs with unique behavior toward such enzymes
have been discovered to have selective anti-herpesvirus activity
(2-9). Among the nucleoside analogs discovered, 9-[(2-hydroxy-
ethoxy)methyl]guanine (acyclovir), one of the new nucleoside
analogs with such activity, was recently licensed in the United
States for the treatment of primary genital herpesvirus infec-
tion and disseminated herpetic infection. Some of the other
compounds are at different stages of clinical development. Re-
cently, an analog of guanosine, 9-[(1,3-dihydroxy-2-propoxy)-
methyl]guanine (DHPG), with the structure shown in Fig. 1,
was synthesized independently by Syntex (Palo Alto, CA) (10)
and Biologics (Toronto, ON, Canada) (11) and was found to have
anti-herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) ac-
tivity. HSV that lacked the ability to induce virally coded thy-
midine kinase (TK) was found to be resistant to DHPG. Never-
theless, phosphonoacetate-resistant HSV, which is crossresistant
to acyclovir, was as sensitive to DHPG as the parental virus,
whereas a marginal activity of DHPG against Epstein-Barr vi-
rus (EBV) and no activity against human cytomegalovirus (CMV)
were reported (11).
In view of the potency and the unique spectrum of antiviral
activity of DHPG, we examined: (i) the activity of this com-
pound against several unique HSV mutants that had either al-
tered TK or DNA polymerase; (ii) its behavior toward HSV-in-
duced TK and its mode of action against HSV-1; and (iii)
sensitivity of several strains ofCMV and EBV to the drug. The
results of the studies are reported in this communication.
EXPERIMENTAL PROCEDURES
Materials. All chemicals used were reagent grade or purer.
DHPG, acyclovir, and phosphonoformate (PFA) were gifts from
Syntex, Wellcome Research Laboratories (Research Triangle
Park, NC), and Astra Laboratories (Sodert3ije Sweden), re-
spectively. ATP and dThd were purchased from Sigma. [2-'4C]-
dThd (53 mCi/mmol; 1 Ci = 3.7 x 1010 Bq) was obtained from
Schwarz/Mann. [3H]DHPG (16 Ci/mmol) was kindly given by
Syntex. The other chemicals or materials were obtained as de-
scribed (12, 13).
Cells. Cells were grown at 370C in RPMI 1640 medium
(GIBCO) containing 100 jg of kanamycin per ml, supple-
mented with 5% horse serum for HeLa S3, 5% fetal bovine serum
for Vero cells, and 10% fetal calf serum for P3HR-1 cells. A hu-
man fibroblast cell strain, WI-38, was cultivated in modified
Eagle's medium containing 100 Ag of streptomycin and 100 units
of penicillin per ml, supplemented with 15% fetal bovine serum.
The WI-38 cells were used between their 22nd and 27th pas-
sages.
Virus. Human CMV strain BT1943, isolated from an organ
transplant, and strain Towne, isolated from a congenitally in-
fected baby, were received from the Wistar Institute. CMV strain
Major isolated from a prostate cell culture was received from
Abbreviations: DHPG, 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine;
HSV-1 and HSV-2, herpes simplex virus types 1 and 2, respectively; TK,
thymidine kinase; EBV, Epstein-Barr virus; CMV, cytomegalovirus;
ED9o, effective dose, 90%; PFA, phosphonoformate.
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F. Rapp. The three strains were used at passages p-4, p-37, and
p-29, respectively. Laboratory strains of HSV SC16 parental
and TK mutants S1, B3, and Tr7 isolated in the presence of
acyclovir at 10 ktg/ml, (E)-5-(2-bromovinyl)-2'-deoxyuridine at
10 ,ug/ml, and acyclovir at 1 ,ug/ml, respectively (14, 15), were
gifts of G. Darby and H. Field (Cambridge University, United
Kingdom). DNA polymerase mutants (PFAr, la, 2a, 3b, 4b, and
5) were cloned isolates of HSV-1 (KOS strain) grown in the
presence of PFA (16). Laboratory strains of virus HSV-1, HSV-
2, and all mutants were maintained as described (12).
The Inhibition of Cell Growth. The procedure for estab-
lishing the ID50 was as described (12).
The Inhibition of Virus Growth: Plaque Reduction Test for
CMV. Extracellular fluid was obtained from virus-infected cells
(BT1943, Major, and Towne) 3-5 days after the culture reached
100% cytopathic effect. The supernatant fluid containing ex-
tracellular virus was divided into. aliquots and was frozen at -700C
for plaque-titration reduction tests.
Confluent WI-38 cells seeded in 3.5-mm diameter multi-well
Petri dishes were infected with 90-100 plaque-forming units in
0.2 ml of medium. After 2 hr of adsorption at 370C in 5% CO2
-in air with adequate agitation, modified Eagle's medium con-
taining 6% fetal bovine serum and various concentrations of
DHPG was added. After 36.hr of incubation, the medium was
replaced with media containing 1% agarose, modified Eagle's
medium, 6% fetal bovine serum, and various concentrations of
DHPG. The second agarose overlayer was, added 6 days after
infection. The final reading was made 9-10 days after infection
-with an inverted microscope.
Assay of the Yield for HSV. To establish the effective dose,
90% (ED90), HeLa S3 cells were seeded in 25-cm2 flasks and
were used as host cells for virus infection. After a 1-hr adsorp-
tion period with virus at 5-10 plaque-forming units per cell, the
monolayers were rinsed with phosphate-buffered saline, fol-
lowed by the addition of 5 ml of growth medium containing
various concentrations of drug. The cells were incubated at 37C
for 24 hr and then were stored frozen at -70°C until titration.
To establish the effect of time exposure of DHPG on HSV-1,
the drug was added and removed at various times after infec-
tion. The cells were rinsed at various times to ensure removal
of all drug. The cells were incubated at 37°C for 24 hr and then
were stored at -70°C until titration. To determine the effect
of various nucleosides on DHPG's antiviral activity, each nu-
cleoside was added with DHPG to the infected cells at time 0.
The cells then were incubated at 37°C for 24 hr and were stored
at -700C until titration.
Virus titration was carried out as described by Cheng et aL
(12) with Vero rather than CV-1 cells.
Determination of EBV Genome Copies per Cell. EBV DNA
was purified from virus isolated from the supernatant fluids of
12-O-tetradecanoylphorbol 13-acetate-induced P3HR-1 cells as
described (17). EBV-specific complementary RNA was synthe-
sized in vitro (18), and complementary RNA-DNA hybridiza-
tion was carried out on nitrocellulose filters according to Gil-
lespie and Spiegelman (19), -except that NaDodSO4 was pres-
ent at a final concentration of 0.1% during the hybridization.
P3HR-1 cells growing exponentially were treated with DHPG
at different concentrations for 5 days. The genome copy num-
bers were estimated by the method described (18).
TK Preparation and Assays. The enzyme activities were es-
timated as described (13). HSV-induced TK was purified from
infected HeLa (BU25)-cells (20) by using affinity column pro-
cedures as described (13, 21). To estimate the amount of DHPG
phosphorylated, [3H]DHPG (60 mCi/mmol) was used instead
of [14CldThd in the TK assay. The solution used for washing
DE81 discs was 1 mM ammonium formate instead of 95%
ethanol. DHPG would not adsorb to the disc, whereas its phos-
phorylated derivatives would. The other conditions of the assay
were the same as for the TK assay (13).
RESULTS AND DISCUSSION
Antiviral Activity of DHPG. The effects of DHPG on the
growth of HSV-1 and HSV-2, on three strains of human CMV,
and on EBV genome replication in P3HR-1 cells, an EBV-pro-
ducing human cell line, were examined; the results are de-
picted in Tables 1, 2, and 3. The -concentration of DHPG that
inhibits 50% of the growth of HeLa S3 cells was 125 AM. This
value is similar to that previously reported (11). DHPG could
effectively inhibit the replication of HSV-1 and HSV-2 at non-
cytotoxic concentrations as reported by Smith et aL (11), as shown
in Table 1. It could also inhibit growth of three different strains
of CMV in'WI-38 cells (Table 2) and decrease the EBV genome
number in P3HR-1 at the noncytotoxic concentrations (Table
3). These observations are in contrast with the previous report
that indicated a lack of activity against EBV and CMV at the
noncytotoxic concentration (11). Fluorescent antibody assay and
radioimmunoassay were employed previously by other inves-
tigators to examine the effect of DHPG on CMV and EBV, re-
spectively. In these assays the expression of virus-specific an-
tigens was examined. Thus, the activity of anti-CMV and EBV
growth activity might have been overlooked. It should be stated
that DHPG at 50 AM had no inhibitory action against the growth
of WI-38, whereas the ID50 for P3HR-1 cells in culture was 40
,uM.
Activity of DHPG Against HSV-1 or DNA Polymerase Mu-
tants. HSV-1 mutants that induced either altered TK (20) or
altered DNA polymerase (16) were examined for their sensi-
tivity to DHPG, the results of which are shown in Table 1. An
HSV-1 mutant (B2006) that could not induce TK in infected cells
was resistant to DHPG. This result is in agreement with the
previous observation (11) and suggests the important role of
virus-induced TK in the action of DHPG against HSV-1. Virus
mutants (B3, Tr7, S1) that induce an altered TK with no ap-
parent change of induced DNA polymerase in infected cells
were still sensitive to DHPG at concentrations far below the
50% cell growth inhibition concentration, in spite of the fact
that those mutants were resistant to acyclovir or (E)-5-(2-bro-
movinyl)-2'-deoxyuridine (21). Lack of crossresistance between
acyclovir and DHPG was observed with the S1 strain of HSV.
'Partial crossresistance between acyclovir and DHPG was in-
Table 1. Anti-HSV activity of DHPG and acyclovir
Virus ED90, ,uM
Parental Selection enzyme Acy-
Type strain Mutant reagent mutant DHPG clovir
HSV-1 KOS - - 2.0 16
KOS PFArj PFA DNA pol 1.0 100
KOS PFAr2 PFA DNA pol 1.0 100
KOS PFAr3 PFA DNA pol 1.8 160
KOS PFAr4 PFA DNA pol 2.6 200
KOS PFAr5 PFA DNA pol 1.5 78
CL101 B2006 BrdUrd TK 200 200
SC16 - - - 0.5 3.5
SC16 Si Acyclovir TK 1.0 200
SC16 B3 BrVdUrd TK 0.5 2.5
SC16 Tr7 Acyclovir TK 16 150
HSV-2 333 - 2.0 -
G - 2.0 -
DNA pol, DNA polymerase; BrVdUrd, (E)-5-(2-bromovinyl)-2'-de-
oxyuridine.
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* Concentration required to inhibit 50% plaque formation.
dicated with the Tr7 strain. Thus, mutations producing resis-
tance to acyclovir due to alteration of induced TK do not nec-
essarily lead to resistance to DHPG, in spite of the structural
similarity of DHPG and acyclovir.
This laboratory recently isolated several HSV-1 variants
(PFArI-PFAr5) with altered DNA polymerase and with no ap-
parent change in induced TK (16). These variants were resistant
to acyclovir and PFA in comparison with the parental strain (KOS).
The change of behavior of acyclovir triphosphate, the phos-
phorylated metabolites, and PFA toward DNA polymerase in-
duced by these variants could be responsible for the resistance.
When the variants were examined for their sensitivity toward
DHPG, they all had sensitivity similar to the parental virus
(KOS). Because there was no apparent change of virus-induced
TK and the mechanism of action of acyclovir was suggested to
be on virus-induced DNA polymerase, the lack of crossresis-
tance between acyclovir and DHPG toward those variants sug-
gested either that acyclovir and DHPG have different effects
on viral DNA polymerase or that DHPG may interfere with
virus replication by a mechanism differing from that of acy-
clovir. These observations require further exploration.
Behavior of HSV-Induced TK Toward DHPG. Virus-in-
duced TK was isolated from cells infected by SC16, B3, Tr7,
and Si of laboratory HSV strains. DHPG was examined as the
substrate of virus-induced TK; the results are depicted in Fig.
2. DHPG could serve as the substrate of all of the TK isolated;
however, the kinetics of DHPG toward different TKs was dif-
ferent. With equivalent TK activity, the optimal DHPG phos-
phorylation relative to dThd phosphorylation was 35%, 120%,
and 80% for SC16, B3, and SI, respectively. The concentrations
required to give 50% of optimal activity were 10, 6, and 20 ,uM
for SC16, B3, and SI, respectively. The kinetics of the reaction
catalyzed by these virus TKs did not follow the Michaelis-Men-
ten kinetic equation. Substrate inhibition was observed for TK
induced by either SI or SC16. This result may relate to the sub-
unit structure of virus-induced TK, which requires further in-
vestigation. In spite of some difference in kinetic parameters
of induced TK by SC16, B3, and Si toward DHPG, the rate
of phosphorylation of DHPG was not much different at 2 ,uM
DHPG when equal activities of TK were used. Because all three
strains of HSV-induced TK activity in cells were within a 3-fold
difference (21), it is conceivable that a similar amount of DHPG
could be phosphorylated in cells infected by any of those three
Table 3. Effects of DHPG on EBV genome copies in P3HR-1 cells
Copies per cell,







P3HR-1 cells were treated with various concentrations of DHPG for
5 days at 37°C. At the end of treatment, cells were harvested and EBV
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FIG. 2. PhosphorylationofDHPGbyHSV-1-inducedTK. Virus-in-
duced TK was purified from HeLa (BU-25) cells infected by different
strains ofHSV (A, B3; o, Si; x, SC16; and o, Tr7 (10 x), as indicated,
with the procedures as described (21). The activity of the enzyme used
per assay was 4.2 microunits, except that, in the case of Tr7, 42 mi-
crounits per assay was used. An enzyme unit is defined as the activity
that catalyzes the phosphorylation of 1 nmol of dThd per min at 37°C
under our assay conditions (13). Assays were performed at 37°C for 1
hr.
strains at 2 ,uM DHPG. This could be responsible for the sim-
ilar sensitivities of the three strains to DHPG. In contrast, the
enzyme from Tn-infected cells seemed to phosphorylate DHPG
to a much lesser extent than did the other virus strains when
equal TK activities were used for comparison. This lesser de-
gree of the rate of DHPG phosphorylation by Tr7 TK could be
responsible for the lesser sensitivity of Tr7 toward DHPG.
Mode of Action Against HSV-1. HSV-1 (KOS)-infected cells
were exposed to DHPG at different-times after infection. The
drug was active when it was added before infection or at 8 hr
after infection. When drug was added at 0 hr after infection and
removed at 8 hr after infection, the antiviral activity of DHPG
was the same as when infected cells were exposed continuously
to DHPG. The antiviral activity could be partially neutralized
by adding 5 ,uM dThd, but not by adding 5 AM guanosine (Ta-
ble 4). Higher concentrations of dThd could not further neu-
tralize DHPG activity. These results suggest that DHPG ex-
erted its action at an early phase of the virus-infection cycle and
Table 4. Effects of the time of exposure of HSV-1-infected cells to
the drug and to the addition of nucleoside on anti-HSV-1 activity
of DHPG
Time of exposure % of control
to DHPG after plaque-forming






0-24 dThd, 5 /&M 39
0-24 Guo,5,M 7
The concentration ofDHPG was 2 pM.
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that its action is irreversible. Furthermore, the neutralization
of antiviral activity by dThd could be related to the decrease
of DHPG phosphorylation by virus-induced TK.
In summary, DHPG is active against HSV-1, HSV-2, EBV,
and CMV at low concentrations relative to the cytotoxicity; the
selective action of DHPG against HSV-1 is virus-TK depen-
dent. The drug has a different spectrum of anti-HSV-1 activity
than does acyclovir. The action of DHPG appears to be quite
irreversible and thus, the drug has great potential for use in
anti-herpesvirus chemotherapy. It should be noted that the
mechanism of the selective action against EBV and CMV should
be quite different from that against HSV-1 and HSV-2, because
there is no definitive evidence that EBV and CMV could in-
duce their specified TKs (1, 22-25). DHPG appears to be at
least as inhibitory as acyclovir against EBV replication (26) and
much more inhibitory against CMV (27).
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